Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Dana-Farber Cancer Institute
Varian, a Siemens Healthineers Company
PMV Pharmaceuticals, Inc
Canadian Cancer Trials Group
National Institutes of Health Clinical Center (CC)
The University of Hong Kong
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Case Comprehensive Cancer Center
University of Chicago
University of Chicago
Boehringer Ingelheim
Aktis Oncology, Inc.
University of Chicago
Tianjin Medical University Cancer Institute and Hospital
Tubulis GmbH
Peter MacCallum Cancer Centre, Australia
University of California, Irvine
Second Affiliated Hospital, School of Medicine, Zhejiang University
Eli Lilly and Company
ViroMissile, Inc.
Dana-Farber Cancer Institute
University Health Network, Toronto
M.D. Anderson Cancer Center
Merus B.V.
AstraZeneca
Tizona Therapeutics, Inc
ALX Oncology Inc.
Case Comprehensive Cancer Center
BioNTech SE
University of Virginia
Betta Pharmaceuticals Co., Ltd.
IDEAYA Biosciences
University of Alberta
University of Colorado, Denver
University of Virginia
University of Alberta
Institut Curie
UNC Lineberger Comprehensive Cancer Center
Theravectys S.A.
Immunolight, LLC
Karolinska University Hospital
Wake Forest University Health Sciences
Daiichi Sankyo
Brigham and Women's Hospital
Oscotec Inc.
Oslo University Hospital
Abramson Cancer Center at Penn Medicine
Kidney Cancer Research Bureau
Wake Forest University Health Sciences